Recombinant Human ICOSLG protein(Met1-Ser258), His-tagged, Biotinylated
Cat.No. : | ICOSLG-3213HB |
Product Overview : | Biotinylated Recombinant Human ICOSLG (NP_056074.1) (Met1-Ser258) was expressed in HEK293 with a C-terminal polyhistidine tag. |
- Specification
- Gene Information
- Related Products
- Download
Source : | HEK293 |
Species : | Human |
Tag : | C-His |
Protein length : | Met1-Ser258 |
Conjugation/Label : | Biotin |
Form : | Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. |
Bio-activity : | Immobilized Recombinant Human ICOS / AILIM / CD278 Protein (His & Fc Tag) at 2 μg/ml (100 μl/well) can bind Recombinant Human ICOS Ligand/B7-H2/ICOSLG Protein(His Tag), Biotinylated, The EC50 is 16-50 ng/mL. |
Molecular Mass : | The recombinant human ICOSLG consists of 251 amino acids and predicts a molecular mass of 28.1 kDa. |
Endotoxin : | < 1.0 EU per μg protein as determined by the LAL method. |
Purity : | > 95 % as determined by SDS-PAGE. |
Storage : | Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
Reconstitution : | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents. |
Gene Name : | ICOSLG inducible T-cell co-stimulator ligand [ Homo sapiens ] |
Official Symbol : | ICOSLG |
Synonyms : | ICOSLG; inducible T-cell co-stimulator ligand; ICOSL; ICOS ligand; B7 homolog 2; B7 homologue 2; B7 H2; B7 related protein 1; B7H2; B7RP 1; B7RP1; CD275; GL50; ICOS L; KIAA0653; B7-like protein Gl50; B7-related protein 1; transmembrane protein B7-H2 ICOS ligand; B7-H2; LICOS; B7RP-1; ICOS-L; |
Gene ID : | 23308 |
mRNA Refseq : | NM_015259 |
Protein Refseq : | NP_056074 |
MIM : | 605717 |
UniProt ID : | O75144 |
Products Types
◆ Recombinant Protein | ||
ICOSLG-598H | Recombinant Human ICOSLG Protein | +Inquiry |
ICOSLG-794H | Recombinant Human ICOSLG Protein, MYC/DDK-tagged | +Inquiry |
ICOSLG-039H | Recombinant Human ICOSLG Protein, His-tagged | +Inquiry |
ICOSLG-90H | Recombinant Human ICOSLG Protein, His (Fc)-Avi-tagged | +Inquiry |
ICOSLG-425H | Recombinant Human ICOSLG protein, Fc-tagged | +Inquiry |
◆ Lysates | ||
ICOSLG-2618MCL | Recombinant Mouse ICOSLG Overexpression Lysate(Met 1-Lys 279) | +Inquiry |
ICOSLG-2804MCL | Recombinant Mouse ICOSLG Overexpression Lysate(Met 1-Lys 279) | +Inquiry |
ICOSLG-1095HCL | Recombinant Human ICOSLG cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (6)
Ask a questionICOSLG protein plays an important regulatory role in the immune system. It binds to ICOS receptors on the surface of T cells and promotes the activation and differentiation of T cells, which in turn affects the strength and direction of the immune response.
Certain biomolecules can serve as molecular markers of ICOSLG proteins, such as mRNAs or proteins of ICOSLG proteins detected in biological samples such as blood and urine. These markers can be used for early diagnosis of disease, prognostic judgment, or monitoring of treatment efficacy.
Factors to be considered in drug development for ICOSLG proteins include drug specificity, safety, pharmacokinetic properties, etc. In addition, the dosage form, route of administration, and dosage of the drug need to be considered to develop an effective treatment plan.
A variety of factors can affect the expression of ICOSLG protein, including cytokines, inflammatory factors, immunostimulants, etc. These factors can stimulate or inhibit the expression of ICOSLG protein, which in turn affects the strength and direction of the immune response.
Therapeutic strategies targeting ICOSLG proteins include inhibition of its activity, modulation of its expression, and gene therapy. For example, the development of small molecule inhibitors or antibody drugs against ICOSLG protein to inhibit its aberrant activity in disease, or the regulation of ICOSLG protein expression through gene knockout or overexpression technology.
Assessing the potential of ICOSLG proteins as drug targets requires a comprehensive analysis. Factors to consider include the structure and function of the ICOSLG protein, its role in the immune system, interactions with existing medications, and potential therapeutic efficacy and safety.
Customer Reviews (3)
Write a reviewICOSLG performed very well in the experiments, with reliable and reproducible results.
The stability is very strong, and it can maintain the stability of its structure and function even after a lot of use, which shows its excellent quality and reliability.
The storage conditions are simple, and it will not be denatured even at ultra-low temperatures.
Ask a Question for All ICOSLG Products
Required fields are marked with *
My Review for All ICOSLG Products
Required fields are marked with *
Inquiry Basket